Skip to main content
. 2024 Mar 15;14(3):1033–1051. doi: 10.62347/EYNT8387

Table 2.

Safety of S-1, number of subjects (%)

Neoadjuvant chemotherapy with S-1 (N = 106)
Patients with any AE 78 (74)
AE leading to death 0 (0)
Any SAE 1 (1)
AE leading to discontinuation of S-1 20 (19)
White blood cell decrease 30 (28)
Anemia 27 (25)
Thrombocytopenia 26 (25)
Bilirubin increase 19 (18)
Pruritus 8 (8)
ALT increase 9 (8)

AE, adverse event; SAE, serious adverse event.